News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Intercell AG Sees U.S. JE Vaccine Approval in Early 2009
December 29, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VIENNA, Dec 29 (Reuters) - Austrian biotech firm Intercell (ICEL.VI) said on Monday it expects U.S. approval for its Japanese Encephalitis (JE) vaccine to move into early 2009, later than expected.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Asia
Europe
MORE ON THIS TOPIC
Job Trends
8 Companies Hiring Now in Regulatory
October 23, 2025
·
2 min read
·
Angela Gabriel
Drug pricing
Trump To Target Trading Partners With Drug Pricing Probe: Report
October 22, 2025
·
1 min read
·
Annalee Armstrong
Podcast
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
October 22, 2025
·
1 min read
·
Heather McKenzie
FDA
Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award
October 21, 2025
·
2 min read
·
Dan Samorodnitsky
